These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study. Skov-Jeppesen K; Veedfald S; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B Bone; 2021 Nov; 152():116065. PubMed ID: 34153529 [TBL] [Abstract][Full Text] [Related]
13. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. Nissen A; Christensen M; Knop FK; Vilsbøll T; Holst JJ; Hartmann B J Clin Endocrinol Metab; 2014 Nov; 99(11):E2325-9. PubMed ID: 25144635 [TBL] [Abstract][Full Text] [Related]
14. The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Asmar M; Asmar A; Simonsen L; Gasbjerg LS; Sparre-Ulrich AH; Rosenkilde MM; Hartmann B; Dela F; Holst JJ; Bülow J Diabetes; 2017 Sep; 66(9):2363-2371. PubMed ID: 28667118 [TBL] [Abstract][Full Text] [Related]
15. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes. Skov-Jeppesen K; Christiansen CB; Hansen LS; Windeløv JA; Hedbäck N; Gasbjerg LS; Hindsø M; Svane MS; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B J Clin Endocrinol Metab; 2024 Jun; 109(7):1773-1780. PubMed ID: 38217866 [TBL] [Abstract][Full Text] [Related]
16. The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans. Krogh LSL; Henriksen K; Stensen S; Skov-Jeppesen K; Bergmann NC; Størling J; Rosenkilde MM; Hartmann B; Holst JJ; Gasbjerg LS; Knop FK Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651162 [TBL] [Abstract][Full Text] [Related]